Announcements Trials
Browse Landscape

Phase

Phase 2 73Phase 1 43Phase 3 30Phase 1/2 13Phase NA 2Phase 2/3 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 32INDUSTRY 27NETWORK 4NIH 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Gemcitabine × Clear all
NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT00022009 2013-09-20

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡